Senores Pharmaceuticals gains on inking pact to acquire ANDA for Enalapril Maleate Tablets
Senores Pharmaceuticals is currently trading at Rs 508.10, up by 4.05 points or 0.80% from its previous closing of Rs 504.05 on the BSE.
The scrip opened at Rs 510.00 and has touched a high and low of Rs 513.85 and Rs 506.00 respectively. So far 5001 shares were traded on the counter.
The BSE group 'B' stock of face value Rs 10 has touched a 52-week high of Rs 664.00 on 19-Mar-2025 and a 52-week low of Rs 440.00 on 13-Jan-2025.
Last one week high and low of the scrip stood at Rs 550.55 and Rs 491.00 respectively. The current market cap of the company is Rs 2351.73 crore.
The promoters holding in the company stood at 45.77%, while Institutions and Non-Institutions held 13.82% and 40.40% respectively.
Senores Pharmaceuticals through its wholly-owned subsidiary Senores Pharmaceuticals, Inc., USA (SPI), has signed agreement to acquire the USFDA-approved Abbreviated New Drug Application (ANDA) for Enalapril Maleate Tablets 2.5mg, 5mg, 10mg and 20mg from Wockhardt.
Enalapril is indicated as a treatment of hypertension, heart failure, and asymptomatic left ventricular dysfunction. The market size of Enalapril Tablet in the USA was around $28.60 million (MAT December 2024) as per IQVIA and around $109.24 million (MAT March 2025) as per the specialty data aggregator Symphony. The acquisition will be funded through the Initial Public Offer (IPO) proceeds raised by Senores Pharmaceuticals. This is in line with the objects of the IPO stated in the Red Herring Prospectus.
Senores Pharmaceuticals is global research driven pharmaceutical company engaged in developing and manufacturing a wide range of generic pharmaceutical products in the B2B segment predominantly for the Regulated Markets across various therapeutic areas and dosage forms.
